Form 4: Arcellx CFO Michelle Gilson Executes Stock Option and Sells Shares

Arcellx's CFO, Michelle Gilson, exercised stock options and sold shares of common stock on September 17, 2024, according to a recent SEC filing.

Summary

• On September 17, 2024, Michelle Gilson, CFO of Arcellx, Inc., exercised a stock option to acquire 15,000 shares of common stock at a price of $8.66 per share.
• Simultaneously, Gilson sold 6,274 shares at a weighted average price of $77.5089 and 8,726 shares at a weighted average price of $77.8809.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan.
• Following these transactions, Gilson directly owns 6,915 shares of Arcellx common stock and holds options for 88,515 shares.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of insider trading activity. The transactions are part of a pre-arranged plan, so they don't necessarily indicate a positive or negative outlook on the company.

Industry Context

This filing is a routine disclosure of insider transactions. It's common for executives to exercise stock options and sell shares, especially under pre-arranged trading plans like Rule 10b5-1, which allows insiders to trade without being accused of acting on non-public information.

Comparison to Industry Standards

• Insider transactions are a normal part of corporate governance and are regularly disclosed by executives at publicly traded companies.
• The use of Rule 10b5-1 trading plans is a common practice among executives to avoid accusations of insider trading.
• Comparing Gilson's transactions to those of other CFOs in similar biotech companies would require analyzing their individual filings and compensation structures.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-arranged nature of the trades mitigates any significant concerns.

Key Dates